Tweets
Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/Spb0ABOMMm https://t.co/wkMurvB0G3
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Lancet - Full Read Review of the Diagnosis and management of ANCA-associated vasculitis
by Stone, et al https://t.co/Lg0FKR8RZ4 https://t.co/RUpK00YmTh
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity
#1 (24%) w/ RP-ILD & high mortality
#2 (14%) dermatomyositis, intermediate prognosis
#3 (62%) arthritis & mechanics hands, good prognosis https://t.co/4NqZp4yR18 https://t.co/rBrhBxxniR
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
ICYMI: Community-Acquired Pneumonia (CAP)
https://t.co/AMConIb14r https://t.co/BCfcHc5i37
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/a3XeAa2lcG https://t.co/dTZa2uQF97
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Polyautoimmunity in RA, Regardless of ACPA Positivity
While it is believed that autoimmunity follows autoantibody positivity, a Danish study shows the incidence of polyautoimmunity to be similar in RA patients who are either ACPA + or -.
https://t.co/7lmp1NB0XX https://t.co/onaEluzkGy
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
19% Arthritis Prevalence in the US
According to NHIS, in 2022, the prevalence of diagnosed arthritis in adults was 18.9% . These numbers are down since the CDC's MMWR report of 2019–'21, where it was estimated 21.2% of U.S. adults had "diagnosed arthritis"
https://t.co/mtYSBHw8Oo https://t.co/NHqjLlwatm
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://t.co/cdSVbuBzXf https://t.co/CUC5v0hSxr
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Fibroblast activation w/ inflammatory arthritis studied by PET to detect fibroblast activation protein (FAP), but decreases after TNF or 17A inhib. Fibroblasts switch from pathogenic (MMP3+/IL6+) to pro-resolving phenotype (CD200+DKK3+) https://t.co/K1xAMqPiuT https://t.co/07NNgW9Lpv
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Review article on inclusion body myositis, a progressive, debilitating myopathy w/ onset > 50 yrs. IBM typically has asmmetric, painless, weakness & atrophy of finger flexors or quadriceps w/ dysphagia. Most are wheelchair bound w/in 13-15 years https://t.co/jybZzCDYk5 https://t.co/FyVA5hveZ4
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
ICYMI: Teaching and Academic Burnout
RheumNow recently highlighted a publication that reported about a third of physicians in academia intend to leave.
https://t.co/uSVVJ6zl73 https://t.co/6BWwd2btMf
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Preoperative Delay & Education Benefits Arthroplasty Patients
A randomized study shows having patients waiting for knee arthroplasty undergo a preoperative program of weight loss, exercise, etc gave them modestly improved pain/function/quality of life.
https://t.co/RSFwhFKq8U https://t.co/xgyQ65mUAO
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago


